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Background: Neurofibromatosis type 1 (NF1) is a hereditary tumor syndrome characterized by the development of
benign nerve-sheath tumors, which transform to malignant peripheral nerve-sheath tumors (MPNST) in about 8 to
13% of patients with NF1. MPNST are invasive sarcomas with extremely poor prognosis, and their development
may correlate with internal tumor load of patients with NF1. Because early identification of patients with NF1 at risk
for developing MPNST should improve their clinical outcome, the aim of this study was to identify serum
biomarkers for tumor progression in NF1, and to analyze their correlation with tumor type and internal tumor load.
Methods: We selected candidate biomarkers for NF1 by manually mining published data sources, and conducted a
systematic screen of 56 candidate serum biomarkers using customized antibody arrays. Serum from 104 patients
with NF1 with and without MPNST, and from 41 healthy control subjects, was analyzed. Statistical analysis was
performed using the non-parametric Mann–Whitney U-test, followed by Bonferroni correction.
Results: Our analysis identified four markers (epidermal growth factor receptor, interferon-γ, interleukin-6, and
tumor necrosis factor-α) for which significantly different serum concentrations were seen in patients with NF1
compared with healthy controls. Two markers (insulin-like growth factor binding protein 1 (IGFBP1) and regulated
upon activation, normal T-cell expressed and secreted (RANTES)) showed significantly higher concentrations in
patients with NF1 and MPNST compared with patients with NF1 without MPNST. A correlation with internal tumor
load was found for IGFBP1.
Conclusion: Our study identified two serum markers with potential for early detection of patients with NF1 at risk
for developing MPNST, and four markers that could distinguish between patients with NF1 and healthy subjects.
Such markers may be useful as diagnostic tools to support the diagnosis of NF1 and for timely identification of
MPNST. Moreover, the data suggest that there is a systemic increase in inflammatory cytokines independently of
tumor load in patients with NF1.
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Neurofibromatosis type 1 (NF1) is an autosomal domin-
ant tumor syndrome, with an estimated incidence at
birth of 1 in 2500 [1] and complete penetrance. NF1 is
caused by mutations in the NF1 gene [2,3], coding for
the tumor-suppressor protein neurofibromin, which acts
as a Ras-negative regulator via its Ras-GTPase activating
protein (GAP) domain. Monoallelic and biallelic loss of
NF1 leads to increased Ras activity in affected cells.
Among the defining features of NF1 is the development
of benign peripheral nerve-sheath tumors, which can arise
at virtually any site in the body. Whereas cutaneous
neurofibromas (CNF) are mostly visible and palpable, sub-
cutaneous neurofibromas, internal plexiform neurofibro-
mas (PNF) and malignant peripheral nerve-sheath tumors
(MPNST) are difficult to detect, quantify, or monitor [4].
MPNST are the major cause for the reduced life span
of patients with NF1, and they will lead to death if not
detected early and treated in time. The primary forms of
treatment are selective resection of benign PNF, and rad-
ical surgical resection of MPNST [5-8]. However, the in-
vasive growth pattern of MPNST frequently prohibits
complete tumor removal, especially when diagnosed late
in their development. Moreover, although chemotherapy
and radiotherapy may delay recurrence, they have little
effect on long-term survival [7,9].
The lifetime risk of MPNST for patients with NF1 pa-
tients has been estimated to be about 8 to 13% and thus
is more than 1000 times higher for these patients than
for the general population. Moreover, many patients
with NF1 develop MPNST at the unusually young age of
around 30 years [10,11], compared with the median age
of diagnosis of 62 years in the general population [12].
Because MPNST develop by malignant progression of
pre-existing PNF, the risk to develop an MPNST increases
to almost 50% in patients with NF1 and PNF [12,13].
It is possible to detect dermal and superficial neuro-
fibromas directly by optical or ultrasonography methods
[14], whereas PNF and MPNST are often diagnosed only
after clinical symptoms occur. Systematic analysis of the
internal tumor load of patients with NF1 by whole-body
magnetic resonance imaging (MRI) suggests an associ-
ation between the risk for MPNST development and in-
ternal PNF tumor load [15]. However, these imaging
techniques are not applicable as a routine screening tool.
The search for surrogate biomarkers for timely iden-
tification of patients at risk for malignant transfor-
mation has mostly been based on the assumption that
overexpression of proteins in PNF and MPNST sub-
sequently leads to increased systemic concentrations
[16-19]. Among such factors, serum levels for midkine
and for stem cell factor were found to be significantly in-
creased in a cohort of 39 patients with NF1, although no
correlation with tumor load or MPNST was found [20].Recently, we identified melanoma-inhibitory activity (MIA;
also known as cartilage-derived retinoic acid-sensitive
protein (CD-RAP)) as a marker for the internal tumor
load in a cohort of 42 patients with NF1 [21]. MIA was
shown previously to be a biomarker for malignant neu-
roectotermal tumors [22]. In another study, 92 genes en-
coding putative secreted proteins in neurofibromas and
MPNST were analyzed for their potential as serum
markers [23]. Of these, only adrenomedullin (ADM)
was confirmed as differentially expressed and in-
creased in the serum of patients with NF1, and serum
concentrations were found to be even higher in a small
sample of patients with MPNST (n = 5).
Tumorigenesis in NF1 is strongly influenced by the
haploinsufficient NF1+/− systemic environment, which
may also promote invasion of PNF and MPNST by
NF1+/− monocytes and mast cells [24-30]. Therefore,
we included immunomodulating cytokines in the present
screen for serum biomarkers, in addition to factors se-
creted by tumor cells in PNF and MPNST. Of the 56 can-
didate proteins analyzed, we identified four proteins with
significantly altered serum concentrations in patients with
NF1 compared with non-NF1 control subjects, but inde-
pendently of tumor load. Two proteins were significantly
increased in patients with MPNST, and one of these also
correlated with internal tumor load.
Methods
Ethics approval
The study was approved by the internal review board
(Ethics Committee of the Ärztekammer Hamburg num-
ber OB-089/04) in compliance with the Declaration of
Helsinki, and informed consent was obtained before
sample collection.
Patients and serum collection
Serum samples from patients with NF1 were obtained
from the Department of Maxillofacial Surgery (University
Hospital Eppendorf, Hamburg, Germany). All patients
with NF1 were clinically diagnosed according to published
guidelines and criteria [31]. Serum samples from healthy
control subjects were obtained from the Institute of Med-
ical Immunology (Charité - Universitätsmedizin Berlin)
from anonymized leftover diagnostic samples. For detailed
information on the patient cohorts, see Additional file 1.
Venous blood (1 to 10 ml) was collected, then separated
by centrifugation within 2 hours of collection, and serum
samples were immediately frozen in aliquots and stored
at −80°C until use. Fresh aliquots were used for each
analysis.
Candidate marker selection
Selection of candidate markers was based on a manual
literature search of publications and publicly available
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or cell supernatants from patients with nervous system
or epithelial tumors or from cell lines, or 2) differential
gene expression between the normal peripheral nervous
system, neurofibroma, and MPNST. and 3) immuno-
modulatory cytokines (see Additional file 2). The list
of identified candidate factors was further reduced by
selecting factors with known functional roles in tumori-
genesis such as growth promotion, migration and metas-
tasis, angiogenesis, and immune modulation, based on
information from the Gene Ontology and GeneCards
databases [32,33]. The final selection of candidate factors
was based on the availability of suitable screening plat-
forms. Of the 115 initially identified potential serum
proteins, a list of 56 candidate factors was compiled for
screening of serum samples based on the availability of
antibodies for customized array analysis (Figure 1, see
Additional file 2).Figure 1 Schematic outline of the candidate marker selection and
for neurofibromatosis type 1 (NF1) tumors consisted of proteins that are
peripheral nerve-sheath tumors (MPNST), have been found to promote
(n = 36). These 115 proteins were selected by manual searches of publ
in two steps, with sera from 60 patients with NF1 in the first pre-screen
proteins (platelet-derived growth factor (PDGF)-BB, insulin-like growth fa
macrophage inflammatory protein (MIP)-4 and TNF-related apoptosis ind
and included in the main screening of 104 NF1 sera, which confirmed
(IL)-6, interferon (IFN)-γ, epidermal growth factor receptor (EGFR), and R
(RANTES)) as potential biomarkers.Serum screening
Customized human cytokine arrays (Quantibody;
RayBiotech Inc., GA, USA) were used to determine se-
rum protein concentrations. Analyses were performed
in accordance with the manufacturer’s instructions. Ima-
ging was performed using the accompanying software
(Quantibody Array Testing Software; RayBiotech Inc.).
Potential marker proteins were initially identified by
screening of 30 candidate proteins using 60 NF1 sera
(n = 27, n = 13, and n = 20, respectively, for patients
with NF1 with PNF, with MPNST, and without tumors)
and 20 control sera. Secondary screening was performed
on the five proteins that showed significant differences
in the pre-screening round (platelet-derived growth
factor (PDGF)-BB, insulin-like growth factor binding
protein (IGFBP)1, tumor necrosis factor (TNF)-α,
macrophage inflammatory protein (MIP)-4, TNF-related
apoptotic ligand (TRAIL)-R2), together with another setscreening procedures. The initial 115 possible serum markers
overexpressed in plexiform neurofibromas (PNF) or malignant
tumor growth (n = 79), or are immunmodulatory cytokines
ished data. Of the 115 initially selected proteins, 56 were screened
ing step, and from 104 patients with NF1 in the second. Five
ctor binding protein (IGFBP)1, tumor necrosis factor (TNF)-α,
ucing ligand (TRAIL)-R2) were selected from the pre-screening step
IGFBP1 and TNF-α, and identified four new proteins (interleukin
egulated upon activation, normal T-cell expressed and secreted
Table 1 Characteristics of patient cohorts recruited for the study
Controls NF1 patients NF1 patients NF1 patients
w/o PNF w/o MPNST with PNF w/o MPNST with MPNST
n 41 35 39 30
mean age in years 47 (range 24–66) 32 (range 14–48) 34 (range 15–63) 34 (range 16–62)
♀/♂ 22/19 22/13 17/22 17/13
whole body MRI 25/35 33/39 30/30
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second round, 104 NF1 sera and 41 control sera were
screened. Altogether, 56 candidate proteins were
screened, and 104 NF1 and 41 control sera were used.
The candidate proteins were simultaneously scanned by
multiplex detection in quadruplicate spots per array.
Hence, all sera were analyzed in at least quadruplicates.
A flowchart of the screening procedure is provided (Fig-
ure 1). Serum factors with significantly different levels
between groups (with the exception of epidermal growth
factor receptor (EGFR)) were verified in a limited subset
of NF1 (n ≥ 11) and control (n ≥ 5) serum samples using
ELISA for IGFBP1 (Abcam, Cambridge, UK), and
cytometric bead array (CBA) (BD Bioscience, Heidel-
berg, Germany) for RANTES (regulated upon activation,
normal T-cell expressed and secreted), interferon (IFN)-γ,
interleukin (IL)-6 and TNF-α. The analyses were
performed in accordance with the manufacturers’ instruc-
tions. Capture beads were analyzed on a flow cytometerFigure 2 Quantitative protein array results of sera from 104 patients
compared with 41 healthy controls (Co). Differences were highly signific
growth factor receptor (EGFR), (D) and tumor necrosis factor (TNF)-α. None
the two groups. Statistical analysis was performed using the non-parametri(FACSCalibur, BD Biosciences, Heidelberg, Germany),
and flow-cytometry data were evaluated with FCAP Array
analysis software (Soft Flow Inc., MN, USA) (see Add-
itional file 3).
Statistical analysis
Serum levels of the candidate markers in the NF1 patient
group and control group were analyzed with respect to
median levels and interquartile ranges. To verify all data
for normal distribution, the Kolmogorov-Smirnov test was
used. Stratified patient groups were compared using the
Mann–Whitney U-test for continuous non-parametric
variables. For assessing the discriminatory power of
individual markers, the receiver operating characteris-
tic (ROC) curve and area under the curve (AUC) were cal-
culated. For significance testing, the non-parametric
Mann–Whitney U-test followed by Bonferroni correction
was used. Two-tailed tests were used for all analyses.
P<0.05 was considered significant. Statistical analysiswith neurofibromatosis type 1 (NF1) (the total group; NF1total)
ant for: (A) interleukin (IL)-6, (B) interferon (IFN)-γ, (C) epidermal
of the other proteins tested showed significant differences between
c Mann–Whitney U-test, including Bonferroni correction.
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Inc., IL, USA) and GraphPad Prism software (version
5.0 GraphPad Software Inc., CA, USA).
Results and discussion
In the present study, we used antibody arrays to identify
serum biomarkers for NF1 in general and for NF1-
associated nerve-sheath tumors in particular. Manual
data mining identified 115 proteins as potential serum
markers for NF1. Of these 115 proteins, 79 are expressed
in PNF or MPNST, or have been described as tumorigenic
serum factors. The other 36 proteins are immunomodula-
tory cytokines. These proteins were selected because of
evidence that systemic NF1 haploinsufficiency in patients
with NF1 may result in overexpression of cytokines
[34,35] (see Additional file 2). We reasoned that the de-
gree of immunological deregulation may indirectly signal
increased risk for tumor growth and malignant transform-
ation. The sera of 104 patients with NF1 with different
tumor types, and 41 matched control subjects (Table 1;
see Additional file 1) were analyzed, and 56 of the 115
initially identified candidate proteins were screened (seeFigure 3 Quantitative protein array results of sera from 41 healthy co
subdivided into three groups. These comprised 35 patients with NF1 wit
nerve-sheath tumors (MPNST) (cutaneous neurofibromas; cNF), 39 patients
MPNST. (A) Insulin-like growth factor binding protein (IGFBP)1 and (B) Reg
(C) IGFBP1 serum concentrations in patients with NF1 with different intern
1 to 99 cm3 = low load; 100 to 500 cm3 = medium load; >500 cm3 = high
Mann–Whitney U-test, including Bonferroni correction (*P≤0.05; **P≤0.01; *Additional file 2). Pre-screening was carried out with
60 sera (comparing controls, NF1 without PNF or
MPNST, NF1 with PNF, and NF1 with MPNST), using
an array of 30 proteins (see Additional file 1), and this
identified 5 proteins with significantly increased levels
in serum of patients with NF1. When testing for these
5 proteins was performed in the complete cohort of
104 patients, only 2 proteins (IGFBP1 and TNF-α)
were confirmed to be significantly different in NF1
sera. We also screened for another 26 proteins in the
complete cohort and found significant differences for
6 proteins (Figure 1).
Serum concentrations of all six candidate markers
were independent of age and sex in the tested popu-
lation (mean age was 46 and 32 years for the healthy
controls and the NF1 group, respectively). This is im-
portant, as circulating levels of the inflammatory cyto-
kines TNF-α and IL-6 may increase with age [36,37].
Significant differences in serum concentration were
found between patients with NF1 and healthy sub-
jects for four proteins (Figure 2). The serum concen-
tration of EGFR was significantly lower and the serumntrols and 104 patients with neurofibromatosis type 1 (NF1)
h no plexiform neurofibromas (PNF) and no malignant peripheral
with NF1 with PNF and no MPNST, and 30 patients with NF1 with
ulated upon activation, normal T-cell expressed and secreted (RANTES).
al tumor loads as measured by MRI-based volumetry (0 cm3 = no load,
load). Statistical analysis was performed using the non-parametric
**P≤0.001).
Table 2 Overview on serum marker features at 90%
sensitivity
NF1 marker MPNST marker
IFN-γ EGFR IL-6 TNF-α IGFBP1 RANTES
Sensitivity: 90,4 90,4 90,4 90,4 90,0 90,0
Specificity: 70,7 14,6 51,2 68,3 50,0 25,7
NPV 88,0 60,3 84,2 87,7 79,3 72,0
PPV 75,5 51,4 64,9 74,0 65,9 58,1
cut off (ng/ml): 0,15 8,57 0,34 0,59 13,77 30,72
The prevalence for NF1 markers was set at 0.5, while the prevalence for
MPNST markers was set at 10%. The risk of NF1 patients to develop an MPNST
is 8-13%.
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TNF-α and IL-6 were significantly higher in patients
with NF1 compared with healthy subjects.
Further stratification of the NF1 cohort into three cli-
nical groups (patients with NF1 with 1) CNF only, 2)
with PNF and 3) with MPNST) (Table 1) identified two
more proteins, IGFBP1 and RANTES, for which there
were significant differences between patients with NF1
with MPNST and those without MPNST. Of note, no
difference was detected between the control group and
patients with NF1 without MPNST (n = 74) for these
two proteins (Figure 3A,B).
A previous study using volumetric analysis of whole-
body MRI data for patients with NF1 indicated aFigure 4 Discrimination between the neurofibromatosis type 1 (NF1)
curves. (A) interleukin (IL)-6, (B) interferon (IFN)-γ, (C) tumor necrosis facto
curves for discrimination between patients with NF1 with and without mal
insulin-like growth factor binding protein (IGFBP)1 and (F) for Regulated upcorrelation between internal tumor load and risk for
malignant transformation of PNF into MPNST [4].
Therefore, we attempted to correlate the serum concen-
tration of the six identified serum biomarkers with in-
ternal tumor load for the 87 patients with NF1 for
which these data were available (see Additional file 1).
Importantly, the serum concentrations of IGFBP1, but
not of any of the other five markers, correlated with in-
ternal tumor load (Figure 3C).
This finding is in line with the correlation between
IGFBP1 serum levels and presence of MPNST (Figure 3A),
and further identifies IGFBP1 as a potential risk marker
for malignant transformation. The data also suggest that
increased cytokine levels in patients with NF1 are inde-
pendent of tumor load. Rather, these results imply that
systemic NF1 haploinsufficiency triggers a permanent and
systemic inflammatory status in patients with NF1, which
is reflected by a significant increase in IFN-γ, TNF-α and
IL-6 [34].
Protein array data were confirmed in a small subgroup
by CBA and ELISA (see Additional file 3) for IFN-γ,
TNF-α, IL-6, IGFBP1 and RANTES. We did not reassess
the level of EGFR because of its comparably lower AUC.
The diagnostic potential of the factors we identified
was determined by computing the AUC of the individual
ROC curves. Specificity was determined at a sensitivity
of 90% (Table 2; Figure 4). For all six candidates thegroup and control group receiver operating characteristic (ROC)
r (TNF)-α and (D) epidermal growth factor receptor (EGFR). The ROC
ignant peripheral nerve-sheath tumors (MPNST) are shown in (E) for
on activation, normal T-cell expressed and secreted (RANTES).
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NF1 markers was found for IFN-γ (0.90), followed by
TNF-α (0.88), IL-6 (0.83) and EGFR (0.73). The in-
creased levels of pro-inflammatory cytokines did not de-
pend on tumor load, as often found for patients with
other tumors [38]. Rather, our data showed an increased
systemic pro-inflammatory state in patients with NF1
compared with non-NF1 controls, supporting our as-
sumption that increased cytokine levels in NF1 are
caused by the NF1+/− environment. Whether this is due
to an increase in mast cells and monocyte activity, or to
other generalized changes in the immune status of these
patients, remains unclear [35,39].
In patients with MPNST, the AUC of IGFBP1 (0.77)
was larger than that of RANTES (0.65) (Figure 4).
RANTES is an inflammatory chemokine known to medi-
ate chemotactic activity in immune cells such as T cells
and monocytes [40]. RANTES was also shown to be
expressed by breast carcinomas [41], and correlated with
a more advanced stage of disease, suggesting a role for
cancer progression. Increased serum levels of RANTES
and IGFBP1 may be the result of increased secretion by
the tumor cells themselves, or by immune cells in res-
ponse to the neoplastic process, or by both mechanisms.
IGFBP1 binds IGF-I and IGF-II, and prolongs their
half-life. Plasma levels of IGFBP1 are regulated by hor-
mones outside of the growth-hormone axis, including
insulin, glucagon, and cortisol [42,43]. An inverse correl-
ation has previously been indicated between IGFBP1
levels and carcinogenesis [44,45]. The expression of IGF-I
and growth-hormone receptors in PNF and MPNST in
patients with NF1, and the correlation between IGF-I
receptor levels and the increased mitosis index of PNFs,
suggest sensitivity of these tumors to IGFBP1-regulated
factors [10,46]. Taken together, IGFBP1 may modulate
IGF access to PNF and MPNST, although this mechanism
still needs to be elucidated.
The reasons for the reduced circulating EGFR levels
that we detected in patients with NF1 are unclear. A
possible functional explanation may be enhanced sur-
vival of cells that retain their EGFR on the cell surface,
providing readiness for EGF signaling [47]. Similarly,
EGF signaling has been shown to enhance tumorigenesis
in NF1 animal models, and NF1-derived Schwann cells
and fibroblasts are highly sensitive to EGF [48]. Hence,
it seems that retaining the EGFR on the cell surface
leads to reduced circulation of soluble EGFR, and pro-
vides an environment that promotes tumorigenesis, as
seen in patients with NF1.
Recently, two studies identified MIA and ADM as
potential NF1 tumor markers in cohorts of 42 and 32
patients, respectively [21,23]. There was also a trend to-
wards correlation between ADM and MPNST, although
the MPNST group was too small to show significance(n = 5). MIA concentration was particularly high in
patients with NF1 with either PNF or large numbers
of neurofibromas, and correlated with internal tumor
burden. Both of these factors seem to be related to
tumor burden in NF1, although induction as a result of
changed systemic environment due to haploinsufficiency
cannot be excluded. It would be intriguing to investigate
further what role, if any, a systemic inflammatory envi-
ronment may play in the early stages of tumorigenesis in
patients with NF1.
Conclusions
Our study encompasses the largest cohort of patients
with NF1 (n = 104) screened to date for potential serum
markers in this rare genetic cancer syndrome. We iden-
tified four potential biomarkers, which may assist in the
diagnosis of NF1, and two further markers (IGFBP1 and
RANTES) that correlate with the presence of MPNST.
Intriguingly, IGFBP1 also seems to correlate with in-
ternal tumor burden, and thus may indicate increased
risk for malignant transformation in patients with NF1.
Furthermore, our data reveal a systemic pro-inflam-
matory profile in patients with NF1, which is probably
caused by NF1 haploinsufficiency. Serum biomarkers
that could aid in the early detection of malignant pro-
gression would be extremely helpful because therapeutic
interventions could be initiated before further spread of
the tumor or development of metastasis takes place.
Both the current and previous data are very promising
for further validation of the data in even larger cohorts.
It would be intriguing to further investigate what, if
any, role a systemic inflammatory environment may
play in the early stages of tumorigenesis in patients
with NF1. Multicenter studies in larger cohorts will
be necessary to validate the identified markers, and to
elucidate a possible role of inflammatory cytokines in
tumorigenesis.Additional files
Additional file 1: List and detailed information of patient and
control cohorts used in the study. Abbreviations: nd, not done.
Additional file 2: List of candidate markers selected by manual
curation of published data and text. The proteins used in the
screenings are shown in bold and italic [49-63].
Additional file 3: Reassessment of protein serum markers
interferon (IFN)-γ, interleukin (IL)-6, tumor necrosis factor (TNF)-α,
insulin-like growth factor binding protein (IGFBP) and Regulated
upon activation, normal T-cell expressed and secreted (RANTES)
by cytometric bead array (CBA) and ELISA (arbitrary serum
concentration units). Between 11 and 15 randomly selected sera from
the different NF1 groups (for IFN-γ, IL-6, TNF-α: all NF1 vs. control; for
IGFBP and RANTES: NF1 with no PNF or MPNST, NF1 with only PNF- and
NF1 with MPNST) and 5 control sera were tested as indicated (ND, not
determined). Where available, associated protein array data are shown.
Statistical analysis is shown for CBA/ELISA data (t-test).
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ADM: Adrenomedullin; AUC: Area under the curve; CBA: Cytometric
bead array; CNF: Cutaneous neurofibromas; EGFR: Epidermal growth
factor receptor; ELISA: enzyme-linked immunosorbent assay (ELISA);
IFN-γ: Interferon-γ; IGF-1: Insulin-like growth factors; IGFBP1: Insulin-like
growth factor binding protein 1; IL-6: Interleukin 6; MIA: Melanoma-inhibitory
activity/cd-rap; MIP-4: Macrophage inflammatory protein-4; MK: Midkine;
MPNST: Malignant peripheral nerve-sheath tumors; MRI: Magnetic resonance
imaging; MRT: Magnetic resonance tomography; NF1: Neurofibromatosis
type 1; PDGF-BB: Platelet-derived growth factor-BB; PNF: Plexiform
neurofibromas; RANTES: Regulated upon activation, normal T-cell expressed
and secreted; ROC: Receiver operating characteristic; TNF-α: Tumor necrosis
factor-α; TRAIL-R2: TNF-related apoptosis inducing ligand-R2.
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